ENLON-PLUS
LOE Approachingatropine sulfate; edrophonium chloride
NDAINJECTIONINJECTABLE
Approved
Nov 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ENLON-PLUS (atropine sulfate; edrophonium chloride) is muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Approved for older for: atropine is an anticholinergic agent indicated in adults, older for: cycloplegia () mydriasis () penalization of the healthy eye in the treatment of amblyopia () 1. First approved in 1991.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENLON-PLUS is a fixed-dose injectable combination of atropine sulfate (anticholinergic) and edrophonium chloride (cholinesterase inhibitor) indicated for cycloplegia, mydriasis, and amblyopia treatment in adults. It works by blocking muscarinic cholinergic receptors to produce pupillary dilation and ciliary muscle paralysis, preventing accommodation. The combination balances atropine's anticholinergic effects with edrophonium's acetylcholinesterase inhibition.
LOE Approaching
With LOE approaching and no published spending data, the brand team is likely in maintenance mode with minimal headcount expansion expected; career growth will depend on defensive strategies rather than market expansion.
Mechanism of Action
muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.